Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy La Jolla Pharmaceutical Company (LJPC) stocks in Canada

Learn how to easily invest in La Jolla Pharmaceutical Company stocks.

La Jolla Pharmaceutical Company is a biotechnology business based in the US. La Jolla Pharmaceutical Company stocks (LJPC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.13 – a decrease of 6.81% over the previous week. La Jolla Pharmaceutical Company employs 59 staff and has a trailing 12-month revenue of around $74.5 million.

How to buy shares in La Jolla Pharmaceutical Company

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LJPC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

La Jolla Pharmaceutical Company stock price (NASDAQ:LJPC)

Use our graph to track the performance of LJPC stocks over time.

La Jolla Pharmaceutical Company shares at a glance

Information last updated 2022-01-24.
Latest market close$4.24
52-week range$3.35 - $7.85
50-day moving average $4.40
200-day moving average $4.17
Wall St. target price$4.00
PE ratio 11.3995
Dividend yield N/A (0%)
Earnings per share (TTM) $0.38

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy La Jolla Pharmaceutical Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

La Jolla Pharmaceutical Company price performance over time

Historical closes compared with the close of $4.24 from 2022-01-27

1 week (2022-01-19) -6.81%
1 month (2021-12-27) -12.94%
3 months (2021-10-28) 10.42%
6 months (2021-07-28) 13.37%
1 year (2021-01-28) -34.16%
2 years (2020-01-28) -39.26%
3 years (2019-01-28) 5.73
5 years (2017-01-27) 20.09

Is La Jolla Pharmaceutical Company under- or over-valued?

Valuing La Jolla Pharmaceutical Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of La Jolla Pharmaceutical Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

La Jolla Pharmaceutical Company's P/E ratio

La Jolla Pharmaceutical Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, La Jolla Pharmaceutical Company shares trade at around 11x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

La Jolla Pharmaceutical Company's EBITDA

La Jolla Pharmaceutical Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.7 million.

The EBITDA is a measure of a La Jolla Pharmaceutical Company's overall financial performance and is widely used to measure a its profitability.

La Jolla Pharmaceutical Company financials

Revenue TTM $74.5 million
Operating margin TTM 26.85%
Gross profit TTM $28.1 million
Return on assets TTM 13.8%
Return on equity TTM 0%
Profit margin 16.67%
Book value $-0.61
Market capitalisation $119.2 million

TTM: trailing 12 months

La Jolla Pharmaceutical Company share dividends

We're not expecting La Jolla Pharmaceutical Company to pay a dividend over the next 12 months.

Have La Jolla Pharmaceutical Company's shares ever split?

La Jolla Pharmaceutical Company's shares were split on a 1:50 basis on 14 January 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your La Jolla Pharmaceutical Company shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for La Jolla Pharmaceutical Company shares which in turn could have impacted La Jolla Pharmaceutical Company's share price.

La Jolla Pharmaceutical Company share price volatility

Over the last 12 months, La Jolla Pharmaceutical Company's shares have ranged in value from as little as $3.35 up to $7.85. A popular way to gauge a stock's volatility is its "beta".

LJPC.US volatility(beta: 2.29)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while La Jolla Pharmaceutical Company's is 2.2904. This would suggest that La Jolla Pharmaceutical Company's shares are significantly more volatile than the average for this exchange and represent a higher risk.

La Jolla Pharmaceutical Company overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California. .

Stocks similar to La Jolla Pharmaceutical Company

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site